SeaStar Medical Holding Corporation (NASDAQ:ICU) is a commercial-stage healthcare company that develops treatments for critically ill patients. As highlighted by GlobeNewswire, SeaStar Medical is scheduled to report its first-quarter financial results after the market closes on Wednesday, May 13, 2026. The company will also host a webcast to discuss its financial performance.
For the quarter, Wall Street projects an earnings per share (EPS) of -$0.83 and revenue of $437.5 thousand. EPS, a key metric for stock analysis, shows how much profit is assigned to each share of stock, so a negative figure indicates a net loss for the period. These estimates suggest analysts expect SeaStar Medical to report another unprofitable quarter, impacting its overall profitability outlook.
SeaStar Medical's recent performance reflects this unprofitability. The company has a negative trailing price-to-earnings (P/E) ratio of -8.26 and an earnings yield of -12.11%. A negative P/E ratio, a critical valuation metric, occurs when a company has lost money over the past year, meaning it is not currently profitable on a per-share basis.
From a valuation perspective, SeaStar Medical's price-to-sales ratio is 10.94. This ratio compares the company's stock price to its total sales. The company's enterprise value-to-operating cash flow ratio is negative at -0.15, which indicates that it is spending more cash on its core business operations than it is generating, a key point for investment analysis.
Despite its negative earnings, SeaStar Medical's financial structure appears stable. It maintains a very low debt-to-equity ratio of 0.05, showing it uses little debt to finance its assets. Additionally, its current ratio of 3.63 suggests a strong ability to pay its short-term bills and obligations as they come due, highlighting its balance sheet strength.
